Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon alpha2b in patients with suboptimal molecular response or stable detectable molecular residual disease after at least two years of imatinib treatment (NordDutchCML009)

Next Previous
Trial Profile

A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon alpha2b in patients with suboptimal molecular response or stable detectable molecular residual disease after at least two years of imatinib treatment (NordDutchCML009)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary) ; Peginterferon alfa-2b (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Acronyms NordDutchCML009

Most Recent Events

  • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
  • 25 Jun 2017 Status changed from recruiting to discontinued as the recruitment of patients was difficult, according the results presented at the 22nd Congress of the European Haematology Association
  • 02 Feb 2017 This trial was discontinued in Netherlands, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top